Aptevo Therapeutics (APVO) Commences Phase 1 Clinical Trial of APVO210 for the Treatment of Autoimmune and Inflammatory Diseases
Tweet Send to a Friend
Aptevo Therapeutics Inc. (NASDAQ: APVO) announced today that it has commenced dosing in a Phase 1 clinical trial of APVO210 ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
